Transfer of Subjects From Subutex/Suboxone to RBP-6300
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine if opioid dependent subjects who are already receiving
Subutex and/or Suboxone can transfer to RBP-6300. Upon completing the study, subjects will
continue their pre-study prescribed dosage of Subutex and/or Suboxone
Phase:
Phase 2
Details
Lead Sponsor:
Indivior Inc.
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone